Stockreport

Syros Presents PK and PD Data at ESMO for SY-1425, Its First-in-Class Selective RARa Agonist, in Genomically Defined AML and MDS Patients

Syros Pharmaceuticals, Inc.  (SYRS) 
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am Check Earnings Report
US:NASDAQ Investor Relations: ir.syros.com
PDF Data from Ongoing Phase 2 Clinical Trial Shows Favorable PK and Evidence of RARa Target Engagement in Patients with Proprietary RARA or IRF8 Biomarkers [Read more]